Figure 1
![Figure 1. Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/7/10.1182_blood-2007-02-073528/2/zh80160706190001.jpeg?Expires=1736047229&Signature=t7uI3RFunA6o5U6aLmO-JTfe~4KuZgloP2v-Gd4Tbq0sFvRdSKzULxrDz0-YbChif6unYZG5VbY6bIQ1Rt7Vrvxhd0u6ndUjZYvoiHkGmYRiesfZEP4UXgjic6iNhCmw26ZpEUIU4q-Kr~gYac1SoojfJl3k0fp5X5Oj8KOy3sQeNAYsMG7WE3Hxh4iX53t1~9-i8GzQvuh8PtijUy~4X0AIHNygd9GLOYOt0mcVWFltYe2OUOu-Jk-eEEmMBhLkMpxuLlxIG7fzCVWTtSBLW4Fr53vTdwIuORfwLNFZuGzA3VDlbNzyn2Cv83JgLwl7l71JxT-x7-6kVgwbu3nglg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).
Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).
